Table of Contents
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Minimal Residual Disease Testing Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Growing prevalence of cancer worldwide, leading to increased demand for accurate and reliable diagnostic tests
3.2.1.2. Increasing adoption of precision medicine approaches
3.2.1.3. Growing trend towards early cancer diagnosis and detection
3.2.2. Restraints
3.2.2.1. Limited availability of skilled healthcare professionals to perform and interpret MRD tests
3.2.2.2. Concerns over the accuracy and reliability of MRD tests
3.2.3. Opportunities
3.2.3.1. Increasing adoption of advanced technologies, such as next-generation sequencing
3.2.3.2. Growing trend towards personalized cancer care, which requires accurate and reliable measurement
3.2.4. Challenges
3.2.4.1. Need for continuous investment in research and development to stay competitive
3.3. Technology Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Minimal Residual Disease Testing Market Overview
4.1. Market Size & Forecast, 2019-2029
4.1.1. By Value (USD Million)
4.2. Market Share and Forecast
4.2.1. By Test Type
4.2.1.1. DNA-Based Test
4.2.1.2. RNA-Based Test
4.2.1.3. Immunological Test
4.2.1.4. Others
4.2.2. By Technology
4.2.2.1. NGS, PCR
4.2.2.2. Flow Cytometry
4.2.2.3. Fluorescence In-Situ Hybridization
4.2.2.4. Others
4.2.3. By Application
4.2.3.1. Hematological Malignancies
4.2.3.2. Solid Tumors
4.2.3.3. Others
4.2.4. By End Use
4.2.4.1. Hospitals
4.2.4.2. Specialty Clinics
4.2.4.3. Diagnostic Laboratories
4.2.4.4. Research and Academic Institutes
4.2.4.5. Others
4.2.5. By Region
4.2.5.1. North America
4.2.5.2. Europe
4.2.5.3. Asia Pacific (APAC)
4.2.5.4. Latin America (LATAM)
4.2.5.5. Middle East and Africa (MEA)
5. North America Minimal Residual Disease Testing Market
5.1. Market Size & Forecast, 2019-2029
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Test Type
5.2.2. By Technology
5.2.3. By Application
5.2.4. By End Use
5.2.5. By Country
5.2.5.1. United States
5.2.5.1.1. By Test Type
5.2.5.1.2. By Technology
5.2.5.1.3. By Application
5.2.5.1.4. By End Use
5.2.5.2. Canada
5.2.5.2.1. By Test Type
5.2.5.2.2. By Technology
5.2.5.2.3. By Application
5.2.5.2.4. By End Use
6. Europe Minimal Residual Disease Testing Market
6.1. Market Size & Forecast, 2019-2029
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Technology
6.2.3. By Application
6.2.4. By End Use
6.2.5. By Country
6.2.5.1. Germany
6.2.5.1.1. By Test Type
6.2.5.1.2. By Technology
6.2.5.1.3. By Application
6.2.5.1.4. By End Use
6.2.5.2. United Kingdom
6.2.5.2.1. By Test Type
6.2.5.2.2. By Technology
6.2.5.2.3. By Application
6.2.5.2.4. By End Use
6.2.5.3. Italy
6.2.5.3.1. By Test Type
6.2.5.3.2. By Technology
6.2.5.3.3. By Application
6.2.5.3.4. By End Use
6.2.5.4. France
6.2.5.4.1. By Test Type
6.2.5.4.2. By Technology
6.2.5.4.3. By Application
6.2.5.4.4. By End Use
6.2.5.5. Spain
6.2.5.5.1. By Test Type
6.2.5.5.2. By Technology
6.2.5.5.3. By Application
6.2.5.5.4. By End Use
6.2.5.6. Belgium
6.2.5.6.1. By Test Type
6.2.5.6.2. By Technology
6.2.5.6.3. By Application
6.2.5.6.4. By End Use
6.2.5.7. Russia
6.2.5.7.1. By Test Type
6.2.5.7.2. By Technology
6.2.5.7.3. By Application
6.2.5.7.4. By End Use
6.2.5.8. The Netherlands
6.2.5.8.1. By Test Type
6.2.5.8.2. By Technology
6.2.5.8.3. By Application
6.2.5.8.4. By End Use
6.2.5.9. Rest of Europe
6.2.5.9.1. By Test Type
6.2.5.9.2. By Technology
6.2.5.9.3. By Application
6.2.5.9.4. By End Use
7. Asia-Pacific Minimal Residual Disease Testing Market
7.1. Market Size & Forecast, 2019-2029
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Technology
7.2.3. By Application
7.2.4. By End Use
7.2.5. By Country
7.2.5.1. China
7.2.5.1.1. By Test Type
7.2.5.1.2. By Technology
7.2.5.1.3. By Application
7.2.5.1.4. By End Use
7.2.5.2. India
7.2.5.2.1. By Test Type
7.2.5.2.2. By Technology
7.2.5.2.3. By Application
7.2.5.2.4. By End Use
7.2.5.3. Japan
7.2.5.3.1. By Test Type
7.2.5.3.2. By Technology
7.2.5.3.3. By Application
7.2.5.3.4. By End Use
7.2.5.4. South Korea
7.2.5.4.1. By Test Type
7.2.5.4.2. By Technology
7.2.5.4.3. By Application
7.2.5.4.4. By End Use
7.2.5.5. Australia & New Zealand
7.2.5.5.1. By Test Type
7.2.5.5.2. By Technology
7.2.5.5.3. By Application
7.2.5.5.4. By End Use
7.2.5.6. Indonesia
7.2.5.6.1. By Test Type
7.2.5.6.2. By Technology
7.2.5.6.3. By Application
7.2.5.6.4. By End Use
7.2.5.7. Malaysia
7.2.5.7.1. By Test Type
7.2.5.7.2. By Technology
7.2.5.7.3. By Application
7.2.5.7.4. By End Use
7.2.5.8. Singapore
7.2.5.8.1. By Test Type
7.2.5.8.2. By Technology
7.2.5.8.3. By Application
7.2.5.8.4. By End Use
7.2.5.9. Vietnam
7.2.5.9.1. By Test Type
7.2.5.9.2. By Technology
7.2.5.9.3. By Application
7.2.5.9.4. By End Use
7.2.5.10. Rest of APAC
7.2.5.10.1. By Test Type
7.2.5.10.2. By Technology
7.2.5.10.3. By Application
7.2.5.10.4. By End Use
8. Latin America Minimal Residual Disease Testing Market
8.1. Market Size & Forecast, 2019-2029
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Technology
8.2.3. By Application
8.2.4. By End Use
8.2.5. By Country
8.2.5.1. Brazil
8.2.5.1.1. By Test Type
8.2.5.1.2. By Technology
8.2.5.1.3. By Application
8.2.5.1.4. By End Use
8.2.5.2. Mexico
8.2.5.2.1. By Test Type
8.2.5.2.2. By Technology
8.2.5.2.3. By Application
8.2.5.2.4. By End Use
8.2.5.3. Argentina
8.2.5.3.1. By Test Type
8.2.5.3.2. By Technology
8.2.5.3.3. By Application
8.2.5.3.4. By End Use
8.2.5.4. Peru
8.2.5.4.1. By Test Type
8.2.5.4.2. By Technology
8.2.5.4.3. By Application
8.2.5.4.4. By End Use
8.2.5.5. Rest of LATAM
8.2.5.5.1. By Test Type
8.2.5.5.2. By Technology
8.2.5.5.3. By Application
8.2.5.5.4. By End Use
9. Middle East & Africa Minimal Residual Disease Testing Market
9.1. Market Size & Forecast, 2019-2029
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Technology
9.2.3. By Application
9.2.4. By End Use
9.2.5. By Country
9.2.5.1. Saudi Arabia
9.2.5.1.1. By Test Type
9.2.5.1.2. By Technology
9.2.5.1.3. By Application
9.2.5.1.4. By End Use
9.2.5.2. UAE
9.2.5.2.1. By Test Type
9.2.5.2.2. By Technology
9.2.5.2.3. By Application
9.2.5.2.4. By End Use
9.2.5.3. Qatar
9.2.5.3.1. By Test Type
9.2.5.3.2. By Technology
9.2.5.3.3. By Application
9.2.5.3.4. By End Use
9.2.5.4. Kuwait
9.2.5.4.1. By Test Type
9.2.5.4.2. By Technology
9.2.5.4.3. By Application
9.2.5.4.4. By End Use
9.2.5.5. South Africa
9.2.5.5.1. By Test Type
9.2.5.5.2. By Technology
9.2.5.5.3. By Application
9.2.5.5.4. By End Use
9.2.5.6. Nigeria
9.2.5.6.1. By Test Type
9.2.5.6.2. By Technology
9.2.5.6.3. By Application
9.2.5.6.4. By End Use
9.2.5.7. Algeria
9.2.5.7.1. By Test Type
9.2.5.7.2. By Technology
9.2.5.7.3. By Application
9.2.5.7.4. By End Use
9.2.5.8. Rest of MEA
9.2.5.8.1. By Test Type
9.2.5.8.2. By Technology
9.2.5.8.3. By Application
9.2.5.8.4. By End Use
10. Competitive Landscape
10.1. List of Key Players and Their Offerings
10.2. Global Minimal Residual Disease Testing Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Covid-19 on Global Minimal Residual Disease Testing Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
12.1. Abbott Laboratories
12.2. Adaptive Biotechnologies
12.3. Agilent Technologies
12.4. ARUP Laboratories
12.5. Bio-Rad Laboratories
12.6. F. Hoffmann-La Roche AG
12.7. Illumina, Inc.
12.8. Invivoscribe, Inc.
12.9. Janssen Diagnostics LLC
12.10. Luminex Corporation
12.11. Myriad Genetics, Inc.
12.12. Natera, Inc.
12.13. QIAGEN N.V.
12.14. Sysmex Corporation
12.15. Thermo Fisher Scientific, Inc.
12.16. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
14.1. Qualitative Research
14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
14.3.1. Secondary Research
14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations